Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 14/20 | 0.80 |
| ▸ | IGF1R | P08069 | 4/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29355191 | 1.00 | ALK (1.00) | ALKEGFRIGF1RKCNH2 | |
| SCHEMBL518047 | 0.91 | ALK (0.84) | ALKEGFRIGF1RKCNH2 | |
| SCHEMBL517293 | 0.91 | ALK (0.84) | ALKEGFRIGF1RKCNH2 | |
| SCHEMBL517390 | 0.91 | ALK (0.84) | ALKEGFRIGF1RKCNH2 | |
| SCHEMBL517457 | 0.91 | ALK (0.83) | ALKEGFRIGF1RKCNH2 | |
| SCHEMBL517784 | 0.91 | ALK (0.83) | ALKEGFRIGF1RKCNH2 | |
| SCHEMBL517786 | 0.91 | ALK (0.83) | ALKEGFRIGF1RKCNH2 | |
| SCHEMBL517785 | 0.91 | ALK (0.83) | ALKEGFRIGF1RKCNH2 | |
| SCHEMBL517503 | 0.91 | ALK (0.83) | ALKEGFRIGF1RKCNH2 | |
| SCHEMBL518394 | 0.91 | ALK (0.83) | ALKEGFRIGF1RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601186-A2 | 4-(1H-INDOL-3-YL)-PYRIMIDINES AS ALK INHIBITORS | AstraZeneca AB (SE) | 2013-06-12 | — | — | EP | claimed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | claimed |
| WO-2012017239-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | claimed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | claimed |
| CN-118318033-A | Cell aggregate comprising pituitary hormone-producing cells and method for producing the same | 住友制药株式会社 | 2024-07-09 | — | — | CN | disclosed |
| CN-118043447-A | Method for preparing cell population containing pituitary tissue and cell population | 住友化学株式会社 | 2024-05-14 | — | — | CN | disclosed |
| EP-3700516-B1 | INHIBITORS OF DUX4 INDUCTION FOR REGULATION OF MUSCLE FUNCTION | SONIC MASTER LTD (VG) | 2024-01-24 | — | — | EP | disclosed |
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-10-03 | — | — | US | disclosed |
| US-20230270851-A1 | METHODS FOR THE TREATMENT OF IDIOPATHIC ORBITAL INFLAMMATION AND RELATED CONDITIONS | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2023-08-31 | — | — | US | disclosed |
| WO-2023077077-A1 | RNA DEGRADERS AND USES THEREOF | ARRAKIS THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20220169703-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-11340231-B2 | Methods of screening for condensate-associated specificity and uses thereof | DEWPOINT THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| WO-2012017239-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012017239-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169703-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | ALK 200/4885EGFR 2414/4885IGF1R 3025/4885 |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ALK, BRAF, ABL1 | ALK 1/4885EGFR 40/4885IGF1R 499/4885 |
| US-20230270851-A1 | METHODS FOR THE TREATMENT OF IDIOPATHIC ORBITAL INFLAMMATION AND RELATED CONDITIONS | IGF1R, IGFBP1, IRS1 | ALK 608/4885EGFR 319/4885IGF1R 1/4885 |
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | ADRM1, VHL, MDM2 | ALK 5/4885EGFR 176/4885IGF1R 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.